Latest Research Study on Acute Coronary Syndrome
The Global Acute Coronary Syndrome Market reached US$ 9.94 billion in 2023 and is expected to reach US$ 14.70 billion by 2031, growing at a CAGR of 5.1% during the forecast period 2024-2031.
Acute Coronary Syndrome (ACS) is a term used to describe a range of conditions associated with sudden reduced blood flow to the heart, including heart attacks (myocardial infarctions) and unstable angina. It occurs when the coronary arteries, which supply blood to the heart, become blocked or narrowed, preventing adequate oxygen from reaching the heart muscle.
ACS is a medical emergency that requires immediate attention. It includes three main conditions:
- Unstable angina – chest pain or discomfort that occurs at rest or with minimal exertion.
- ST-elevation myocardial infarction (STEMI) – a severe heart attack caused by a complete blockage of a coronary artery.
- Non-ST-elevation myocardial infarction (NSTEMI) – a heart attack that doesn’t cause the classic ST-segment elevation on an electrocardiogram (ECG), but still results in heart muscle damage.
The key symptoms of ACS are chest pain, shortness of breath, sweating, and nausea. Risk factors include high blood pressure, high cholesterol, smoking, and diabetes. Treatment for ACS often involves medications like blood thinners, pain relief, and surgical interventions such as angioplasty or bypass surgery. Early diagnosis and intervention are crucial for improving outcomes and reducing the risk of long-term heart damage.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/acute-coronary-syndrome-market
Market Growth Drivers:
The increasing prevalence of the chronic disease across the globe and rising technological advancements are driving market growth.
The acute coronary syndrome market is growing due to the rising prevalence of chronic conditions like heart failure, cardiovascular disease, and coronary artery disease, largely driven by unhealthy lifestyles and changing global environments. According to the National Health and Nutrition Examination Survey (NHANES) data from 2020, around 6.2 million American adults aged 20 and older (2.2%) are affected by heart failure. More than 5.7 million Americans are living with heart failure, and approximately 915,000 new cases are diagnosed each year. For patients with advanced heart failure, ventricular assist devices help support the heart by pumping blood throughout the body.
A 2022 report by the American Heart Association highlights that Medicare patients with coronary artery disease from socioeconomically disadvantaged practices face a higher risk of being hospitalized for unstable angina. The increasing prevalence of coronary artery diseases is significantly contributing to the growth of the acute coronary syndrome market.
The high cost associated with acute coronary syndrome treatment will hamper the market’s growth.
In price-sensitive regions like Asia, the high cost of acute coronary syndrome treatments presents a significant challenge to market growth. In these areas, both patients and doctors often opt for more affordable therapies or surgeries. The expensive nature of acute coronary syndrome treatments remains one of the major barriers to broader adoption and market expansion in these regions.
Market Segments:
- By Type: ST-elevation Myocardial Infarction, Non-ST-Elevation Myocardial Infarction, Unstable Angina
- By Drugs: Antithrombotic, Antihypertensive, Statin Drugs
- By End-User: Hospital, Specialty Clinics, Others
- By Region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa
Top Key Players:
- Teva Pharmaceuticals
- Dr. Reddy’s Laboratories
- Boehringer Ingelheim
- Johnson & Johnson
- Merck
- Novartis
- Amgen Inc.
- AbbVie Inc.
- AstraZeneca PLC
- GlaxoSmithKline Plc
Customize Your Scope: https://www.datamintelligence.com/customize/acute-coronary-syndrome-market
Regional Growth
The North American region holds the largest global acute coronary syndrome market.
North America leads the acute coronary syndrome market and is expected to maintain this dominance throughout the forecast period. This growth can be attributed to the increasing prevalence of heart failure, the growing geriatric population, and strong healthcare infrastructure. Additionally, higher investments in research and development have contributed to the region’s market leadership.
The rising rates of chronic conditions like myocardial infarction, unstable angina, and other heart diseases, driven by unhealthy lifestyles and poor diets, have further increased the demand for acute coronary syndrome treatments in North America. According to the American Heart Association (2020), about 790,000 Americans experience heart attacks annually. The growing number of individuals affected by cardiovascular diseases, along with technological advancements and strategic mergers or acquisitions by major players, continue to fuel the demand for acute coronary syndrome treatment in the region.
